Use of recombinant human erythropoietin in two-stage total knee arthroplasty for infection

F. D. Cushner, J. R. Locker, A. D. Hanssen, D. J. Jacofsky, W. N. Scott, G. R. Scuderi, L. Woodard, R. L. Barrack

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A multicenter prospective study was conducted to determine whether epoetin alfa could be used to lower transfusion requirements after two-stage exchange arthroplasty for infection. Forty-one consecutive patients undergoing successful two-stage exchange arthroplasty for an infected total knee arthroplasty were enrolled in a prospective study. Epoetin alfa (40,000 units) was administered subcutaneously after prosthesis resection and antibiotic spacer placement. Although there was no difference in the hemoglobin levels before resection arthroplasty or on postoperative Day 3 between the study group and the control group, hemoglobin levels before reimplantation were higher in the patients who received epoetin alfa (12.4 mg/dL; range, 9.3-15.1 mg/dL) compared with the control group (11.3 mg/dL; range, 8.1-14.4 mg/dL). Average increase in hemoglobin level in the interval between stages was higher in the treatment group (3.2 mg/dL; range, -0.7-6.8 mg/dL) than the control group (1.7 mg/dL; range, -1.9-6 mg/dL). The transfusion rate decreased from 83% of patients in the control group to 34% in the study group during reimplantation. In addition, overall incidence of transfusion for either stage improved from 89% in the control group to 44% in the patients treated with epoetin alfa. Perioperative epoetin alfa statistically increased the hemoglobin levels and decreased transfusion rates for patients undergoing two-stage revision for infected total knee arthroplasty.

Original languageEnglish (US)
Pages (from-to)116-123
Number of pages8
JournalClinical Orthopaedics and Related Research
Issue number392
StatePublished - 2001
Externally publishedYes

Fingerprint

Epoetin Alfa
Knee Replacement Arthroplasties
Erythropoietin
Hemoglobins
Control Groups
Arthroplasty
Infection
Replantation
Prospective Studies
Multicenter Studies
Prostheses and Implants
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Surgery

Cite this

Cushner, F. D., Locker, J. R., Hanssen, A. D., Jacofsky, D. J., Scott, W. N., Scuderi, G. R., ... Barrack, R. L. (2001). Use of recombinant human erythropoietin in two-stage total knee arthroplasty for infection. Clinical Orthopaedics and Related Research, (392), 116-123.

Use of recombinant human erythropoietin in two-stage total knee arthroplasty for infection. / Cushner, F. D.; Locker, J. R.; Hanssen, A. D.; Jacofsky, D. J.; Scott, W. N.; Scuderi, G. R.; Woodard, L.; Barrack, R. L.

In: Clinical Orthopaedics and Related Research, No. 392, 2001, p. 116-123.

Research output: Contribution to journalArticle

Cushner, FD, Locker, JR, Hanssen, AD, Jacofsky, DJ, Scott, WN, Scuderi, GR, Woodard, L & Barrack, RL 2001, 'Use of recombinant human erythropoietin in two-stage total knee arthroplasty for infection', Clinical Orthopaedics and Related Research, no. 392, pp. 116-123.
Cushner FD, Locker JR, Hanssen AD, Jacofsky DJ, Scott WN, Scuderi GR et al. Use of recombinant human erythropoietin in two-stage total knee arthroplasty for infection. Clinical Orthopaedics and Related Research. 2001;(392):116-123.
Cushner, F. D. ; Locker, J. R. ; Hanssen, A. D. ; Jacofsky, D. J. ; Scott, W. N. ; Scuderi, G. R. ; Woodard, L. ; Barrack, R. L. / Use of recombinant human erythropoietin in two-stage total knee arthroplasty for infection. In: Clinical Orthopaedics and Related Research. 2001 ; No. 392. pp. 116-123.
@article{d2dd25045ecd4b57aad97ce51a87c181,
title = "Use of recombinant human erythropoietin in two-stage total knee arthroplasty for infection",
abstract = "A multicenter prospective study was conducted to determine whether epoetin alfa could be used to lower transfusion requirements after two-stage exchange arthroplasty for infection. Forty-one consecutive patients undergoing successful two-stage exchange arthroplasty for an infected total knee arthroplasty were enrolled in a prospective study. Epoetin alfa (40,000 units) was administered subcutaneously after prosthesis resection and antibiotic spacer placement. Although there was no difference in the hemoglobin levels before resection arthroplasty or on postoperative Day 3 between the study group and the control group, hemoglobin levels before reimplantation were higher in the patients who received epoetin alfa (12.4 mg/dL; range, 9.3-15.1 mg/dL) compared with the control group (11.3 mg/dL; range, 8.1-14.4 mg/dL). Average increase in hemoglobin level in the interval between stages was higher in the treatment group (3.2 mg/dL; range, -0.7-6.8 mg/dL) than the control group (1.7 mg/dL; range, -1.9-6 mg/dL). The transfusion rate decreased from 83{\%} of patients in the control group to 34{\%} in the study group during reimplantation. In addition, overall incidence of transfusion for either stage improved from 89{\%} in the control group to 44{\%} in the patients treated with epoetin alfa. Perioperative epoetin alfa statistically increased the hemoglobin levels and decreased transfusion rates for patients undergoing two-stage revision for infected total knee arthroplasty.",
author = "Cushner, {F. D.} and Locker, {J. R.} and Hanssen, {A. D.} and Jacofsky, {D. J.} and Scott, {W. N.} and Scuderi, {G. R.} and L. Woodard and Barrack, {R. L.}",
year = "2001",
language = "English (US)",
pages = "116--123",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "392",

}

TY - JOUR

T1 - Use of recombinant human erythropoietin in two-stage total knee arthroplasty for infection

AU - Cushner, F. D.

AU - Locker, J. R.

AU - Hanssen, A. D.

AU - Jacofsky, D. J.

AU - Scott, W. N.

AU - Scuderi, G. R.

AU - Woodard, L.

AU - Barrack, R. L.

PY - 2001

Y1 - 2001

N2 - A multicenter prospective study was conducted to determine whether epoetin alfa could be used to lower transfusion requirements after two-stage exchange arthroplasty for infection. Forty-one consecutive patients undergoing successful two-stage exchange arthroplasty for an infected total knee arthroplasty were enrolled in a prospective study. Epoetin alfa (40,000 units) was administered subcutaneously after prosthesis resection and antibiotic spacer placement. Although there was no difference in the hemoglobin levels before resection arthroplasty or on postoperative Day 3 between the study group and the control group, hemoglobin levels before reimplantation were higher in the patients who received epoetin alfa (12.4 mg/dL; range, 9.3-15.1 mg/dL) compared with the control group (11.3 mg/dL; range, 8.1-14.4 mg/dL). Average increase in hemoglobin level in the interval between stages was higher in the treatment group (3.2 mg/dL; range, -0.7-6.8 mg/dL) than the control group (1.7 mg/dL; range, -1.9-6 mg/dL). The transfusion rate decreased from 83% of patients in the control group to 34% in the study group during reimplantation. In addition, overall incidence of transfusion for either stage improved from 89% in the control group to 44% in the patients treated with epoetin alfa. Perioperative epoetin alfa statistically increased the hemoglobin levels and decreased transfusion rates for patients undergoing two-stage revision for infected total knee arthroplasty.

AB - A multicenter prospective study was conducted to determine whether epoetin alfa could be used to lower transfusion requirements after two-stage exchange arthroplasty for infection. Forty-one consecutive patients undergoing successful two-stage exchange arthroplasty for an infected total knee arthroplasty were enrolled in a prospective study. Epoetin alfa (40,000 units) was administered subcutaneously after prosthesis resection and antibiotic spacer placement. Although there was no difference in the hemoglobin levels before resection arthroplasty or on postoperative Day 3 between the study group and the control group, hemoglobin levels before reimplantation were higher in the patients who received epoetin alfa (12.4 mg/dL; range, 9.3-15.1 mg/dL) compared with the control group (11.3 mg/dL; range, 8.1-14.4 mg/dL). Average increase in hemoglobin level in the interval between stages was higher in the treatment group (3.2 mg/dL; range, -0.7-6.8 mg/dL) than the control group (1.7 mg/dL; range, -1.9-6 mg/dL). The transfusion rate decreased from 83% of patients in the control group to 34% in the study group during reimplantation. In addition, overall incidence of transfusion for either stage improved from 89% in the control group to 44% in the patients treated with epoetin alfa. Perioperative epoetin alfa statistically increased the hemoglobin levels and decreased transfusion rates for patients undergoing two-stage revision for infected total knee arthroplasty.

UR - http://www.scopus.com/inward/record.url?scp=0035159145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035159145&partnerID=8YFLogxK

M3 - Article

C2 - 11716372

AN - SCOPUS:0035159145

SP - 116

EP - 123

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 392

ER -